Table 4 Definition of subsequent (second-line) treatments

ALK+

Alectinib

80%^a

PbCT/lorlatinib

20%^a

BSC

Crizotinib

80%^a

Alectinib

20%^a

BSC

EGFR+

Osimertinib

70%^a

PbCT

30%^a

BSC

Erlotinib/Gefitinib/Afatinib/Dacomitinib

70%^a

Osimertinib

30%^a

BSC

ROS1+

Crizotinib/Clinical trial/Entrectinib

80%^a

PbCT

20%^a

BSC

 TPS ≥50%

Pembrolizumab/Cisp+pmtrx/Clinical trial

60.80%^b

PbCT

39.20%^b

BSC

 TPS < 50%

Cisp+pemetrexed

46.60%^c

immunotherapies/doce+nintedanib

53.40%^c

BSC

carb+paclitx+beva

46.60%^c

immunotherapies/doce+nintedanib

53.40%^c

BSC

cisp+pmtrx+pembrolizumab

30.50%^c

Doce+nintedanib

69.50%^c

BSC

carb+paclitx+beva+atezolizumab

30.50%^c

Doce+nintedanib

69.50%^c

BSC